Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... 2 Small Business Innovation and Research (SBIR) grant from the National ... of Health (NIH) to support the development of GenVec,s vector production ... 2 0081205/DC50112LOGO ) , , ...
... WAYNE, Pa., Aug. 24 Encorium Group, Inc. (Nasdaq: ... (CRO) that provides design, development, and management capabilities for clinical ... pharmaceutical companies, today announced its financial results for the second ... As previously announced, on July 16, 2009 the Company sold ...
... , JACKSONVILLE, Fla., Aug. 24 In response ... to deploy social networking tools for their members or constituents, ... the Engageon Association Builder (EAB). The first launch was developed ... at www . lipid.org . ...
Cached Biology Technology:GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2Encorium Reports Second Quarter 2009 Financial Results 2Encorium Reports Second Quarter 2009 Financial Results 3Encorium Reports Second Quarter 2009 Financial Results 4Encorium Reports Second Quarter 2009 Financial Results 5Encorium Reports Second Quarter 2009 Financial Results 6Encorium Reports Second Quarter 2009 Financial Results 7Encorium Reports Second Quarter 2009 Financial Results 8Encorium Reports Second Quarter 2009 Financial Results 9Engageon Releases First Peer-to-Peer Medical Association Social Network 2
(Date:10/22/2014)... 2014  Leading identity analyst firm Acuity Market Intelligence ... world,s population will have a chip-based National eID card, ... . Asia , with its vast ... more than 60% of all National eID cards issued ... "The Global National eID Industry Report: 2014 ...
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... that has shown promise in skin disease and hemophilia might ... a new study by researchers at Stanford University School of ... in the Proceedings of the National Academy of Sciences the ... introduce a healthy copy of the gene dystrophin into mice ...
... the process that controls plant growth may help explain ... international team of scientists. , ,Researchers from Purdue ... the first time that proteins similar to multi-drug resistant ... cells, said Purdue plant cell biologist Angus Murphy. Because ...
... Although researchers over recent years have established a foothold ... by which it might contribute to aging and lifespan ... researchers studying p53 function in fruit flies show new ... a guardian against tumor formation, normal levels of p53 ...
Cached Biology News:Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 2Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 3Plant gene related to cancer treatment may foster new oncology drugs 2Plant gene related to cancer treatment may foster new oncology drugs 3New clues to the dark side of a key anti-tumor guardian 2
... S2 cells are used for heterologous protein ... (DES). The S2 cell line was derived ... hours old) Drosophila melanogaster embryos (1). ... room temperature without CO2 and is easily adapted ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
... For our novel expression vectors, we in-troduced ... dual controls: (i) at tran-scriptional level at the ... replication level by amplifying the plasmid copy number, ... is that it retains practically all of the ...
... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
Biology Products: